



PFW
PATENT


Case Docket No. NEREUS.069A
Date: September 13, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Mitchell, et al.
Appl. No. : 10/673,036
Filed : September 25, 2003
For : MACROCYCLIC LACTAMS
Examiner : Kifle, Bruck
Group Art Unit : 1624

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 13, 2004


(Date)
Marc T. Morley, Reg. No. 52,051


TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement in one (1) page.
- (X) A PTO Form 1449 listing and enclosing thirteen (13) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Mitchell, et al.
App. No. : 10/673,036
Filed : September 25, 2003
For : MACROCYCLIC LACTAMS
Examiner : Kifle, Bruck
Group Art Unit : 1624

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing thirteen (13) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9/13/04

By: Marc T. Morley

Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,036
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Mitchell, et al.	
SEP 15 2004 (USE SEVERAL SHEETS IF NECESSARY)		FILING DATE September 25, 2003	GROUP 1624



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
1	Alm, et al. "Effects of topically Applied PGF _{2α} and its Isopropylester on Normal and Glaucomatous Human Eyes." <i>Prog. Clin. Biol. Res.</i> 312: 447-58 (1998).	
2	"Bioreversible Carriers in Drug Design: Theory and Application," edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987).	
3	Fenical, William. "Chemical Studies of Marine Bacteria: Developing a New Resource." <i>Chem. Rev.</i> 93:1673-1683 (1993).	
4	Fingl, et al. <i>Basis of Therapeutics</i> . 5 th Edition. Macmillan Publishing Co. Chp. 13. "Drugs Effective in the Therapy of the Epilepsies," (1975).	
5	Fingl, et al. <i>Basis of Therapeutics</i> . 5 th Edition. Macmillan Publishing Co. Chp. 17. "Analgesic-Antipyretics, Anti-Inflammatory Agents, and Drugs Employed in the Therapy of Gout," (1975).	
6	Fingl, Edward. <i>Basis of Therapeutics</i> . 5 th Edition. Macmillan Publishing Co. Chp. 49. "Laxatives and Cathartics," (1975).	
7	Higuchi, et al. "Pro-drugs as Novel Delivery Systems." <i>A.C.S. Symposium Series</i> , American Chemical Society. 14(3): 154-183 (1975).	
8	Joshi, A. "Microparticulates for Ophthalmic Drug Delivery." <i>J. Ocul. Pharmacol.</i> , 10(1):29-45 (1994).	
9	Khokhlova, et al. "A Chemical Study of the Major Vitamycin Component." Institute of Microbiology, Academy of Sciences of the USSR, Moscow, pgs. 841-845, Russian (1964).	
10	Krassilnikov, et al. "A New Species in the Group of <i>Actinomyces Aurantiacus</i> ," pgs. 482-489 (1960).	
11	Mayer et al. "Efficacy of a Novel Hydrogel Formulation in Human Volunteers." <i>Ophthalmologica</i> . 210(2):101-3 (1996).	
12	Mordini, et al. "Intraocular Pharmacokinetics and Safety of a Humanized Monoclonal Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation." <i>Toxicol. Sci.</i> 52(1):101-6 (1999).	
13	Shedden, et al. "Efficacy and Tolerability of Timolol Maleate Ophthalmic Gel-Forming Solution Versus Timolol Ophthalmic Solution in Adults with Open-Angle Glaucoma or Ocular Hypertension: A Six-Month, Double-Masked, Multicenter Study." <i>Clin. Ther.</i> , 23(3): 440-50 (2001).	

S:\DOCS\MTM\MTM-6823.DOC sma090204

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	